Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Open-Label Extension of Nusinersen for SMA
NCT02594124Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2015
- Primary completion
- Aug 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 14
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Nov 2015; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02594124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594124.